SCOPUS 정보 검색 플랫폼

Clinical and Translational Oncology

Volumn 15, Issue 11, 2013, Pages 965-968

Chemotherapy management of malignant pleural mesothelioma: A phase II study comparing two popular chemotherapy regimens

(2) Habib, E E a Fahmy, E S a

a CAIRO UNIVERSITY (Egypt)

Author keywords

Chemotherapy; Gemcitabine; Mesothelioma; Pemetrexed

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; PEMETREXED;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEARING IMPAIRMENT; HUMAN; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84886592687 PISSN: 1699048X EISSN: 16993055 Source Type: Journal
DOI: 10.1007/s12094-013-1015-3 Document Type: Article

Times cited : (11)

References (20)

1
- 0024356233
- Absence of components of coagulation and fibrinolysis pathways in situ in mesothelioma
- DOI 10.1016/0049-3848(89)90445-3
- Wojtukiewicz MZ, Zacharski LR, Memoli VA et al (1989) Absence of components of coagulation and fibrinolysis pathways in situ in mesothelioma. Thromb Res 55:279-284 (Pubitemid 19209316)
- (1989) Thrombosis Research , vol.55 , Issue.2 , pp. 279-284
- Wojtukiewicz, M.Z.¹ Zacharski, L.R.² Memoli, V.A.³ Kisiel, W.⁴ Kudryk, B.J.⁵ Rousseau, S.M.⁶ Stump, D.C.⁷

2
- 3042770917
- Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies
- DOI 10.1016/j.jtcvs.2004.02.021, PII S0022522304003964
- Sugarbaker DJ, Jaklitsch MT, Bueno R et al (2004) Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 128:138-146 (Pubitemid 38881208)
- (2004) Journal of Thoracic and Cardiovascular Surgery , vol.128 , Issue.1 , pp. 138-146
- Sugarbaker, D.J.¹ Jaklitsch, M.T.² Bueno, R.³ Richards, W.⁴ Lukanich, J.⁵ Mentzer, S.J.⁶ Colson, Y.⁷ Linden, P.⁸ Chang, M.⁹ Capalbo, L.¹⁰ Oldread, E.¹¹ Neragi-Miandoab, S.¹² Swanson, S.J.¹³ Zellos, L.S.¹⁴

3
- 4744366677
- External beam radiation therapy for the treatment of pleural mesothelioma
- DOI 10.1016/S1547-4127(04)00108-2, PII S1547412704001082
- Baldini EH (2004) External beam radiation therapy for the treatment of pleural mesothelioma. Thorac Surg Clin 14:543-548 (Pubitemid 39314488)
- (2004) Thoracic Surgery Clinics , vol.14 , Issue.4 SPEC. ISS. , pp. 543-548
- Baldini, E.H.¹

4
- 26444458845
- Advances in malignant mesothelioma
- DOI 10.1056/NEJMra050152
- Robinson BW, Lake RA (2005) Advances in malignant mesothelioma. N Engl J Med 353:1591-1603 (Pubitemid 41434638)
- (2005) New England Journal of Medicine , vol.353 , Issue.15 , pp. 1591-1603
- Robinson, B.W.S.¹ Lake, R.A.²

5
- 0036837690
- Activity of chemotherapy and immunotherapy on malignant mesothelioma: A systematic review of the literature with meta-analysis
- DOI 10.1016/S0169-5002(02)00180-0, PII S0169500202001800
- Berghmans T, Paesmans M, Lalami Y et al (2002) Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38:111-121 (Pubitemid 35157753)
- (2002) Lung Cancer , vol.38 , Issue.2 , pp. 111-121
- Berghmans, T.¹ Paesmans, M.² Lalami, Y.³ Louviaux, I.⁴ Luce, S.⁵ Mascaux, C.⁶ Meert, A.P.⁷ Sculier, J.P.⁸

6
- 0025103273
- Phase II trial of carboplatin in the management of malignant mesothelioma
- Raghavan D, Gianoutsos P, Bishop J et al (1990) Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 8:151-154 (Pubitemid 20032458)
- (1990) Journal of Clinical Oncology , vol.8 , Issue.1 , pp. 151-154
- Raghavan, D.¹ Gianoutsos, P.² Bishop, J.³ Lee, J.⁴ Young, I.⁵ Corte, P.⁶ Bye, P.⁷ McCaughan, B.⁸

7
- 0025668640
- Carboplatin in malignant mesothelioma: A phase ii study of the cancer and leukaemia group b
- Vogelzang NJ, Goutsou M, Corson JM et al (1990) Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukaemia Group B. Cancer Chemother Pharmacol 27:239-242
- (1990) Cancer Chemother Pharmacol , vol.27 , pp. 239-242
- Vogelzang, N.J.¹ Goutsou, M.² Corson, J.M.³

8
- 19944433589
- Pemetrexed in malignant pleural mesothelioma
- Hazarika M, White RM, Booth BP et al (2005) Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 11:982-992 (Pubitemid 40175745)
- (2005) Clinical Cancer Research , vol.11 , Issue.3 , pp. 982-992
- Hazarika, M.¹ White Jr., R.M.² Booth, B.P.³ Wang, Y.-C.⁴ Lee Ham, D.Y.⁵ Cheng, Y.L.⁶ Rahman, A.⁷ Gobburu, J.V.S.⁸ Li, N.⁹ Sridhara, R.¹⁰ Morse, D.E.¹¹ Lostritto, R.¹² Garvey, P.¹³ Johnson, J.R.¹⁴ Pazdur, R.¹⁵

9
- 0041629528
- Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
- DOI 10.1200/JCO.2003.11.136
- Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636-2644 (Pubitemid 46606305)
- (2003) Journal of Clinical Oncology , vol.21 , Issue.14 , pp. 2636-2644
- Vogelzang, N.J.¹ Rusthoven, J.J.² Symanowski, J.³ Denham, C.⁴ Kaukel, E.⁵ Ruffie, P.⁶ Gatzemeier, U.⁷ Boyer, M.⁸ Emri, S.⁹ Manegold, C.¹⁰ Niyikiza, C.¹¹ Paoletti, P.¹²

10
- 0029928641
- Chemotherapy in malignant pleural mesothelioma: A review
- Ong ST, Vogelzang NJ (1996) Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 14:1007-1017 (Pubitemid 26085549)
- (1996) Journal of Clinical Oncology , vol.14 , Issue.3 , pp. 1007-1017
- Ong, S.T.¹ Vogelzang, N.J.²

11
- 0023718503
- A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A southwest oncology group study
- Zidar BL, Green S, Pierce HI et al (1988) A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a southwest oncology group study. Invest New Drugs 6:223-226
- (1988) Invest New Drugs , vol.6 , pp. 223-226
- Zidar, B.L.¹ Green, S.² Pierce, H.I.³

12
- 0001219320
- Gemcitabine for malignant mesothelioma: A phase II study of the cancer and leukemia group B (CALGB 9530)
- Millard FE, Herndon J, Vogelzang MR et al (1997) Gemcitabine for malignant mesothelioma: a phase II study of the cancer and leukemia group B (CALGB 9530). Proc Am Soc Clin Oncol 16:1710
- (1997) Proc Am Soc Clin Oncol , vol.16 , pp. 1710
- Millard, F.E.¹ Herndon, J.² Vogelzang, M.R.³

13
- 0001461276
- Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma
- Bischoff HG, Manegold C, Knopp M et al (1998) Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 17:1784
- (1998) Proc Am Soc Clin Oncol , vol.17 , pp. 1784
- Bischoff, H.G.¹ Manegold, C.² Knopp, M.³

14
- 0028825114
- A proposed new international TNM staging system for malignant pleural mesothelioma: From the international mesothelioma interest group
- Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma: from the International Mesothelioma Interest Group. Chest 108:1122-1128
- (1995) Chest , vol.108 , pp. 1122-1128
- Rusch, V.W.¹

15
- 0003575141
- National Cancer Institute: April 30
- National Cancer Institute: Common Toxicity Criteria Manual, NCI-CTC version 2.0, April 30, 1999. http://ctep.cancer.gov/reporting/ctc.html
- (1999) Common Toxicity Criteria Manual, NCI-CTC Version 2.0

16
- 0043132304
- Pemetrexed and cisplatin for malignant pleural mesothelioma: A new standard of care?
- DOI 10.1200/JCO.2003.02.043
- Rusch VW (2003) Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care? J Clin Oncol 21:2629-2630 (Pubitemid 46606302)
- (2003) Journal of Clinical Oncology , vol.21 , Issue.14 , pp. 2629-2630
- Rusch, V.W.¹

17
- 20244374653
- Phase i clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma
- Hughes A, Calvert P, Azzabi A et al (2002) Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20:3533-3544
- (2002) J Clin Oncol , vol.20 , pp. 3533-3544
- Hughes, A.¹ Calvert, P.² Azzabi, A.³

18
- 33645449947
- Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma
- DOI 10.1200/JCO.2005.04.3190
- Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A (2006) Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24:1443-1448 (Pubitemid 46622011)
- (2006) Journal of Clinical Oncology , vol.24 , Issue.9 , pp. 1443-1448
- Ceresoli, G.L.¹ Zucali, P.A.² Favaretto, A.G.³ Grossi, F.⁴ Bidoli, P.⁵ Del Conte, G.⁶ Ceribelli, A.⁷ Bearz, A.⁸ Morenghi, E.⁹ Cavina, R.¹⁰ Marangolo, M.¹¹ Soto Parra, H.J.¹² Santoro, A.¹³

19
- 1342267614
- Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
- DOI 10.1093/annonc/mdh059
- Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15:257-260 (Pubitemid 38262625)
- (2004) Annals of Oncology , vol.15 , Issue.2 , pp. 257-260
- Byrne, M.J.¹ Nowak, A.K.²

20
- 34247227282
- Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage
- Fennell D, Steele J, Sheaff M et al (2005) Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage. Lung Cancer 49:S220
- (2005) Lung Cancer , vol.49
- Fennell, D.¹ Steele, J.² Sheaff, M.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.